Ultragenyx Pharmaceutical Inc (0LIF)
LSE
The current 0LIF market cap is 5.32B. The company's latest EPS is USD -7.3878 and P/E is -6.38.
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
Total Revenue | 103.71M | 271.03M | 351.41M | 363.33M | 434.25M |
Operating Income | -424.17M | -330.12M | -381.74M | -648.92M | -569.21M |
Net Income | -402.73M | -186.57M | -454.03M | -707.42M | -606.64M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
Total Assets | 1.14B | 1.76B | 1.52B | 1.55B | 1.49B |
Total Liabilities | 481.73M | 605.18M | 599.84M | 1.19B | 1.22B |
Total Equity | 653.76M | 1.15B | 922.56M | 352.49M | 275.41M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
Operating | -345.38M | -132.22M | -338.71M | -380.47M | -474.81M |
Investing | -13.04M | -179.12M | -195.37M | -291.65M | 168M |
Financing | 679.31M | 600.27M | 118.55M | 501.21M | 388.14M |
Market Cap | 5.32B |
Price to Earnings Ratio | -6.38 |
Price to Sales Ratio | 8.91 |
Price to Cash Ratio | 18.11 |
Price to Book Ratio | 14.05 |
Dividend Yield | - |
Shares Outstanding | 82.11M |
Average Volume (1 week) | 770 |
Average Volume (1 Month) | 1.27k |
52 Week Change | 0.00% |
52 Week High | 64.79 |
52 Week Low | 64.79 |
Spread (Intraday) | 0 (0%) |
Company Name | Ultragenyx Pharmaceutical Inc |
Address |
corporation trust center wilmington, delaware 19801 |
Website | https://www.ultragenyx.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.